DNA synthesis and molecular cloning are tools used by synthetic biologists to create the biological "parts" needed to design and engineer biological devices and systems.
As described before, synthetic biology captures a diverse, multi-disciplinary field. No matter which definition(s) becomes accepted, the ability to make and manipulate DNA is a vital component to practicing synthetic biology.
A large number of parts have been made by the synthetic biology community. Many can be found as part of the Registry of Standard Biological Parts. These modular genetic components are designed to be easy to acquire and assemble to facilitate the building of more complex biological devices. To learn more about the Registry and the biological parts known as BioBricks™, see the entry for the iGEM Registry.
The Registry of Standard Biological Parts is an attempt to create an annotated and characterized repository of biological parts. It is motivated in part because synthetic biologists rely on the ability to make testable biological units. While the parts registry is a useful resource, it is not comprehensive. The ability to manipulate and create genetic material is a necessary skill for being a successful synthetic biologists. This page details how to create DNA from small (<60 nts) oligonucleotides to larger genes (~400 nts) to genome sized (~500 ,000 nts) biological units. Many of the methods found here are the basis for the construction of the registry itself.
Oligonucleotides are chemically synthesized from DNA phosphoramidite monomers. Briefly, activated phosphoramidite monomers are added in the 3' to 5' direction using a cyclical activation and blocking chemistry to obtain a DNA polymer linked by phosphodiester bonds.
Chemical synthesis is currently limited to oligonucleotides of about 200 nt in length.
Gene synthesis, or artificial gene synthesis, refers to the process of creating a nucleic acid template for a gene in vitro, without the requirement of a preexisting DNA template. Soon after the elucidation of the genetic code and the description of the central dogma of molecular biology, there arose a need to synthesize genes de novo in order to study their biological function both in the test tube and in model organisms. Chemical synthesis of DNA has grown from an expensive and time-consuming process into a viable commercial industry capable of high-throughput manufacture of almost any scale of custom DNA molecules in almost any context. This allows species-specific gene optimization, creation of genes from rare or dangerous sources, and combinatorial assembly of any DNA sequence that can be chemically synthesized, even including non-traditional bases. The most advanced applications of gene synthesis have been applied to the recent creation of completely synthetic minimal genomes in prokaryotes.
Despite nearly four decades of progress in gene synthesis technologies, most DNA sequences used in modern molecular biology are assembled in part or in whole from naturally occurring templates. However this limits the scope and applications to previously existing genes and the results of large-scale genomic surveys of novel genes from nature. Modern gene synthesis relies heavily on advancements in chemical DNA oligonucleotide synthesis, with the primary challenges being scale, cost, fidelity and the eventual assembly of complete gene products.
An extensive, but not comprehensive, directory of commercial gene synthesis providers can be found at Genespace.
History of Gene Synthesis
Gene synthesis predates the invention of restriction enzymes and molecular cloning techniques by several years. The first gene to be completely synthesized in vitro was a 77-nt alanine transfer RNA by the laboratory of Har Gobind Khorana in 1972 . This was the result of nearly five years of work and resulted in a DNA template without promoter or transcriptional control sequences. The first peptide- and protein-producing synthetic genes were created in 1977 and 1979, respectively [2, 3]. Steady advancement has led to recent synthesis of complete gene clusters tens of thousands of nucleotides in length, and ultimately a bacterial genome approximately 1.1 million bases in length .
It is impractical for most synthetic biologists to synthesize more than several kilobases of completely synthetic DNA. It is often desirable to build bigger pieces at lower costs and faster speeds than de novo synthesis is currently able to accomplish.
Over the years, many different strategies have been developed to assemble DNA in flexible ways that suit different purposes. These strategies typically employ purification of enzymes that are known to modify DNA in specific ways and these methods of action can be exploited for designing and building specific sequences of DNA. For example, restriction enzymes are used to cut DNA in a specific manner upon recognition of a specific nucleotide sequence. Polymerases and endonucleases add or remove nucleotides to make double stranded DNA from a single stranded template or to create single stranded DNA from double stranded DNA. Many of the modern techniques take advantage of recombination machinery that break DNA from one location to reattach it to another location. In other cases, the endogenous enzymes in a host are utilized to manipulate DNA without the need for prior purification. For example, in some methods endogenous DNA ligase is used to repair single stranded breaks (known as "nicks") to complete the formation of fully circular DNA.
Ultimately, these methods generally require transformation into a host where endogenous enzymes are used to complete the genetic manipulation and replicate (clone) the genetic material. This allows for the expression of the desired proteins to test the ability of the engineered system or for the purification of the genetic material itself such that it can be used for further manipulation, study, or storage.
While there are many specific protocols for the numerous methods of cloning, most share reasonable overlap in their underlying mechanisms of action. Broadly speaking, methods may rely primarily on restriction enzymes, polymerase chain reaction (PCR), or on homologous recombination [5, 6].
Restriction enzymes recognize a specific nucleotide sequence and then cut the DNA in such a way that results in a double stranded break. If the enzyme cuts within or near the recognition site, it is classified as a Type II restriction enzyme. Restriction enzymes can also be classified by if the DNA break results in a straight cut resulting in a blunt end or with a jagged cut resulting in a sticky end.
For example: EcoRI digestion produces "sticky" ends,
whereas SmaI restriction enzyme cleavage produces "blunt" ends:
The Registry of Biological Parts has developed standards for the type and position of restriction enzyme sites to be used when building DNA using restriction enzymes in order to ensure compatibility in the connecting of biological parts. Two of the more popular standards are named and listed below:
One modification to the standard restriction enzyme method is the use of an enzyme that recognizes a non-palindromic sequence. This results in the ability to cut with a single restriction enzyme and still maintain directionality of the biological part.
- CpoI directional cloning
Other methods have been developed that utilize Type II restriction enzymes. These enzymes cut away from their recognition site. This strategy has the advantage over Type I enzymes in their reduction of a "scar" sequence and ability to generate combinatorial libraries.
Polymerase Chain Reaction
Polymerase Chain Reaction (PCR) is a fast and reliable way of making multiple copies of specific sequences of DNA. The PCR methods typically allows for relatively simple and fast construction of genes by linking multiple shorter oligonucleotides together in a series of steps where the earlier PCR product acts as a primer that results in a longer DNA fragment that itself can act as a primer for subsequent rounds of PCR. An exception is TOPO TA cloning, which utilizes the propert of Taq polymerase to leave a single A nucleotide overhang after the PCR reaction. In combination with an optimized vector with a T nucleotide overhang and a topoisomerase that recognizes the vector at the T overhang position, the insert and vector that are annealed at the T and A nucleotides are sealed into a circular vector efficiently.
Oligonucleotide precursors are linked together leaving gaps that must be filled in by DNA polymerase. In the most common method, polymerase cycling assembly (PCA), DNA oligonucleotides are designed to be part of either the top or bottom of the final DNA duplex. Cycles of annealing and polymerase extension result in a growing DNA duplex built from smaller oligonucleotide fragments. A final round of PCR is done with constant primers that amplify the complete desired gene product. Initial oligo linkage is done for 20-30 cycles and full-length PCR is carried out for 20-30 additional cycles.
Oligos must be designed carefully to have similar melting temperatures and be free of interfering secondary structures (high GC content, hairpins, etc.)
- Ligation Independent Cloning (LIC) 
- TOPO TA Cloning (Invitrogen) 
- Uracil-Specific Excision Reagent (USER) (NEB) 
- Splice by Overlap Extension (SOE) PCR 
- Polymerase Cycling Assembly (PCA) 
In 2009, Daniel Gibson of J. Craig Venter's group reported a method for assembling hundreds of kilobases of DNA sequence using an isothermal enzymatic setup known today as "Gibson Assembly". Sub-fragments of the eventual assembly product are obtained as blunt-ended double-stranded DNA molecules several kilobases in length. They share several hundred bases of homology at their adjacent termini. T5 DNA Exonuclease chews back the double-stranded DNA molecule to reveal 3' single-stranded overhangs. Being heat-liable, T5 exonuclease is inactivated after several minutes at the reaction temperature. A mixture of thermostable ligase and DNA polymerase repair and assemble the individual fragments into larger molecules. This method has been used to assemble nonfunctional DNA molecules up to 900 kilobases in length, as well as the complete 16.3 kilobase mouse mitochondrial genome . The size limit of molecules that can be assembled in this manner is currently limited to the cost of design and screening the final assembly products and the hundreds of kilobases of DNA that must be sequenced.
- SLIC sequence and ligation independent cloning T4 DNA polymerase (exonuclease) [22, 23]
- Cre/Lox P1 phage (BD Creator from Clontech)
- att lambda (Gateway Cloning from Life Technologies) 
- Gibson T5 exonuclease, Phusion polymerase, Taq ligase 
- CPEC circular polymerase extension cloning 
- SLiCE (Seamless Ligation Cloning Extract) in vitro homologous recombination 
- Mating-assisted genetically integrated circuit (MAGIC)-bacterial mating 
- ET recombination 
- Transformation-associated recombination 
Moving Forward: Scaling Up Gene Synthesis
The methods below are not new methods and some are already being used commercially. What they offer for the future are methods for potentially scaling up production while decreasing costs. As mentioned before, cost and speed are major limitations preventing de novo DNA synthesis from becoming standard practice.
An alternative gene synthesis technique using solid-phase synthesis of a DNA duplex has been created by several companies, including Blue Heron. In these methods, DNA oligonucleotides are synthesized as in other techniques, they are annealed into complementary short duplexes without overhanging ends, and these duplexes are chemically ligated on a solid phase such as a liquid chromatography column. The complete synthetic DNA duplex is then eluted and used for downstream processes, such as cloning or gene expression.
DNA oligonucleotides have become a commodity and the price per base has been steadily dropping. But there is still great expense involved in large-scale gene synthesis. For a several kilobase gene fragment, oligo cost alone can still exceed $1,000. To over come this hurdle, multiplex parallel gene synthesis technologies are under development, including inkjet DNA printers, photolithography and electrochemical parallel synthesis.
Microfluidic microchips are a common multiplexing solution. In the method of Tian et al. , oligonucleotides are synthesized while coupled to a microchip at their 3' end. The overall process is similar to traditional oligo synthesis, except that individual wells are photoactivated before addition of the next base onto the 5' end. After chemical cleavage of the complete oligo from the microchip, they are hybridized and purified using complementary "quality assurance" oligos bound to magnetic beads. This method eliminates oligos that have either incorporated extra bases or undergone deletions. Final yield from each synthesis well is only around 5 fmol of oligo, which is not sufficient for downstream applications. A final amplification step using common PCR primers to all oligos increases yields up to a million-fold. Oligos can then be assembled by overlap PCR-based methods such as polymerase assembly multiplexing, or PAM. This method has resulted in the synthesis, amplification and expression of a 14.5 kb, 21-gene 30S ribosomal protein operon from E. coli.
One major roadblock remaining in synthetic gene synthesis is overcoming natural error rates in DNA synthesis chemistry. Phosphoramidite oligo synthesis currently has an error rate of 1 in ~160. This results in a high enough error rate in assembled genes that screening and sequencing are major cost bottlenecks, as is the repair or re-synthesis of mutated genes. While the development of cheap and high-throughput sequencing technologies will streamline the screening process, oligo synthesis error rates must also be reduced.
Currently, oligo pools are often screened against complementary reference libraries that can be reused. Oligos that do not completely base-pair with their designed sequence are either washed away in purification steps or are cleaved by DNA mismatch repair proteins due to their imperfect base-pairing. This has currently decreased error rates to 1 in 106, on the order of error rates in DNA polymerases.
J. Craig Venter's team at JCVI have worked to carry gene synthesis to its most advanced level - the creation of a completely synthetic genome. Initially, the JCVI team synthesized a 582,970-base pair "minimized" genome of Mycoplasma genitalium using a stepwise assembly . The genome was divided into 24 cassettes of about 24 kb each which were synthesized by commercial manufacturers. These overlapping cassettes were enzymatically stitched together into bacterial artificial chromosomes, which were attached in a stepwise fashion using a combination of restriction digestion and in vitro recombination. At the point where the molecules were "quarter genomes", they were transformed into yeast where in vivo recombination machinery assembled the full M. genitalium chromosome. This was only proof of synthesis, however, and not of a synthetic genome useful for supporting a living organism.
In 2010, the JCVI team reported the creation of a bacterium controlled by a fully synthetic genome. The 1.08 mega-base pair genome of Mycoplasma mycoides was synthesized and transplanted into a M. capricolum recipient cell to create synthetic bacterium nicknamed "Synthia". The genome was divided into 1,078 1-kb cassettes, which were synthesized by Blue Heron. These cassettes were assembled in yeast using in vivo homologous recombination using a three-step hierarchy that built fragments of ~10,000 bp, ~100,000 bp and finally the complete 1.08 mega-bp genome. These were then isolated carefully from contaminating yeast DNA and transplanted into the recipient bacteria. A selectable marker placed in the synthetic genome demonstrated that bacteria that grew after transplantation were controlled by the synthetic genome. The same team demonstrated that a semi-synthetic genome could be assembled and transplanted using a combination of natural and synthetic DNA.
In 2011, a group from Johns Hopkins reported the first partially synthetic eukaryotic genome. They edited approximately 1% of the Saccharaomyces cerevisiae genome to eliminate introns, repetitive sequence and retrotransposons, replaced all TAG stop codons with TAA, and introduced recombigenic LoxPSym sites to aid in future large-scale manipulations of the genome .
Overall error rates in synthetic genome assembly were controlled by careful cassette synthesis and verification, as well as relying on high-fidelity in vivo recombination methods for hierarchical construction. Even low error rates can have huge effects, though. One single base deletion in the genome was in an essential gene, dnaA, and delayed progress for many weeks. Isolation, growth and manipulation of mega-base pair DNA molecules either in vivo or in vitro is a difficult roadblock as well.
Final assembly of large double-stranded DNA products into kilobase and megabase functional molecules, free of errors and with minimal cost remains a process bottleneck for gene and genome synthesis. In vitro recombination methods have been successfully used to assemble large DNA molecules on the order of tens of kilobases, but this method remains prone to errors and requires considerable homology be engineered into assembly fragments.
- Gibthon - Gibson assembly design program
- j5: A tool for designing DNA assembly with recombination from Nathan Hillson The manual has an excellent overview of recombination-based cloning strategies like SLIC and Gibson. 
- Review of Cloning techniques from ASU
Notes to self:
Rob Carlson website and nature biotech paper on "The Changing Economics of DNA synthesis," report
Practical example of DNA synthesis genscript, blog idt
Nathan's SLIC explanation
Error fetching PMID 412251:
Error fetching PMID 85300:
Error fetching PMID 15616567:
Error fetching PMID 18218864:
Error fetching PMID 19363495:
Error fetching PMID 19745056:
Error fetching PMID 20488990:
Error fetching PMID 20935651:
Error fetching PMID 21601685:
Error fetching PMID 21918511:
Error fetching PMID 21601682:
Error fetching PMID 21364738:
Error fetching PMID 22126803:
Error fetching PMID 21750718:
Error fetching PMID 18985154:
Error fetching PMID 19649325:
Error fetching PMID 17293868:
Error fetching PMID 22328425:
Error fetching PMID 20385581:
Error fetching PMID 17907578:
Error fetching PMID 16289702:
Error fetching PMID 17389646:
Error fetching PMID 2357375:
Error fetching PMID 19111926:
Error fetching PMID 7590320:
Error fetching PMID 2235490:
Error fetching PMID 7580902:
Error fetching PMID 9321675:
Error fetching PMID 9771703:
Error fetching PMID 11076863:
Error fetching PMID 17702758:
Error fetching PMID 8552668:
Error fetching PMID 15731760:
Error fetching PMID 22241772:
Error fetching PMID 3045756:
Error fetching PMID 2020554:
Error fetching PMID 1658796:
- Error fetching PMID 4571075:
- Error fetching PMID 412251:
- Error fetching PMID 85300:
- Error fetching PMID 20488990:
- Error fetching PMID 21601682:
Gene Synthesis Review
- Error fetching PMID 19111926:
- Error fetching PMID 18985154:
- Error fetching PMID 21364738:
- Error fetching PMID 22126803:
- Error fetching PMID 21750718:
- Error fetching PMID 2235490:
- Error fetching PMID 7580902:
- Error fetching PMID 9321675:
- Error fetching PMID 2020554:
- Error fetching PMID 1658796:
- Error fetching PMID 17389646:
- Error fetching PMID 3045756:
- Error fetching PMID 2357375:
- Error fetching PMID 7590320:
- Error fetching PMID 19363495:
oligonucleotide assembly in vitro
- Error fetching PMID 20935651:
- Error fetching PMID 17293868:
- Error fetching PMID 22328425:
- Error fetching PMID 17907578:
- Error fetching PMID 16289702:
- Error fetching PMID 20385581:
- Error fetching PMID 11076863:
Gateway lambda Int
- Error fetching PMID 17702758:
Gateway lambda Cre
- Error fetching PMID 18218864:
- Error fetching PMID 19745056:
oligonucleotide assembly in yeast
- Error fetching PMID 21601685:
- Error fetching PMID 19649325:
//T5 exonuclease recombination
- Error fetching PMID 22241772:
- Error fetching PMID 15731760:
MAGIC, bacterial mating approach
- Error fetching PMID 9771703:
- Error fetching PMID 8552668:
Transformation-associated recombination (TAR) cloning
- Error fetching PMID 15616567:
- Error fetching PMID 21918511:
- j5 DNA Assembly Design Automation Software doi: 10.1021/sb2000116